Naveen Yarlagadda is an Oncology physician affiliated with Winthrop Rockefeller Foundation. OpenAlex indexes 21 publications with 410 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8901 Carti Way
Little Rock, AR 722056523
Telephone
501-906-3000Provider last certified this registry record 28 Sept 2022.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202511 payments$13,989openpaymentsdata.cms.gov ↗
- Geron CorporationProgram year20251 payment
- Lilly USA, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.3%PD-1 inhibitor51.4%Nivolumab69%Pembrolizumab32%Keytruda0%Part D + Part B<11 patientsNucleoside Metabolic Inhibitor1%Fluorouracil100%Part B, office-administered≥13 patients+ 9 more classes in this area
Blood & clotting
21.5%Iron, parenteral preparations15.7%Ferric derisomaltose100%Part B, office-administered≥83 patientsErythropoiesis-stimulating Agent5.7%Epoetin alfa100%Procrit0%Part D + Part B<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
14.4%Substance P/Neurokinin-1 Receptor Antagonist9.5%Aprepitant100%Part B, office-administered≥15 patientsSerotonin-3 Receptor Antagonist4.4%Palonosetron hcl40%Granisetron hydrochloride33%Ondansetron hydrochloride24%Ondansetron Odt3%Part D + Part B≥50 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”